{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80","upperLimit":"97","value":"92"},{"groupId":"OG001","lowerLimit":"81","upperLimit":"97","value":"92"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"1-year survival rate is defined as the percentage of participants still alive at year after the first dose of stud drug.","dispersionType":"95% Confidence Interval","groups":[{"description":"In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle. for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone"},{"description":"In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once, on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once, on Days 1 through 21 of a 28-day cycle. Includes 3 participants who received 2.23 mg/m\\^2 in Phase 1.","id":"OG001","title":"Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year after first dose of study drug","title":"Phase 2: 1 Year Survival Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}